A RADICAL NEW WAY TO TREAT SOLID TUMORS
Powerful & precise T cell therapy that attacks
solid tumors while sparing normal cells
Innovating new treatments for solid tumors
A2 Bio proprietary Tmod™ platform has the ability to absolutely distinguish tumor from normal cells
This is accomplished by integrating multiple signals, overcoming the limits of conventional single-target therapies and by exploiting common, specific gene losses only found in tumor cells
The Tmod™ precision-targeting cell therapy platform aims the powerful armaments of immune cells at tumors, while protecting normal cells. A2 Bio has a first-mover advantage in exploiting the loss of genetic material in cancer cells.
Modular and flexible, our platform is designed to enable a broad pipeline of both autologous and allogeneic cell products that access a large array of unexploited therapeutic targets, including targets previously constrained by toxicity.
Led by a management team with over 90 years of combined experience in cell therapy and biotechnology, A2 Bio is guided by our science and relentless focus to bring forward bold solutions that alter the course of cancer treatment.
November 7, 2022
A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022
March 4, 2022
A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers
March 2, 2022
A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients